223 related articles for article (PubMed ID: 35426424)
1. [Ketamine's fast-acting antidepressant mechanisms: state of the art and new research perspectives].
Marcatili M; Stefana A; Sala C; Conti L; Colmegna F; Clerici M; Dakanalis A
Riv Psichiatr; 2022; 57(2):57-66. PubMed ID: 35426424
[TBL] [Abstract][Full Text] [Related]
2. Human induced pluripotent stem cells technology in treatment resistant depression: novel strategies and opportunities to unravel ketamine's fast-acting antidepressant mechanisms.
Marcatili M; Sala C; Dakanalis A; Colmegna F; D'Agostino A; Gambini O; Dell'Osso B; Benatti B; Conti L; Clerici M
Ther Adv Psychopharmacol; 2020; 10():2045125320968331. PubMed ID: 33224469
[TBL] [Abstract][Full Text] [Related]
3. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
4. Changes in neurotrophic signaling pathways in brain areas of the chronic mild stress rat model of depression as a signature of ketamine fast antidepressant response/non-response.
Derosa S; Misztak P; Mingardi J; Mazzini G; Müller HK; Musazzi L
Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jan; 128():110871. PubMed ID: 37793481
[TBL] [Abstract][Full Text] [Related]
5. Ketamine: The final frontier or another depressing end?
Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
[TBL] [Abstract][Full Text] [Related]
6. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
7. [Ketamine's antidepressant effect: focus on ketamine mechanisms of action].
De Maricourt P; Jay T; Goncalvès P; Lôo H; Gaillard R
Encephale; 2014 Feb; 40(1):48-55. PubMed ID: 24434007
[TBL] [Abstract][Full Text] [Related]
8. Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.
Ionescu DF; Felicione JM; Gosai A; Cusin C; Shin P; Shapero BG; Deckersbach T
Harv Rev Psychiatry; 2018; 26(6):320-339. PubMed ID: 29465479
[TBL] [Abstract][Full Text] [Related]
9. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
10. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB
J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761
[TBL] [Abstract][Full Text] [Related]
11. KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
Abdallah CG; Adams TG; Kelmendi B; Esterlis I; Sanacora G; Krystal JH
Depress Anxiety; 2016 Aug; 33(8):689-97. PubMed ID: 27062302
[TBL] [Abstract][Full Text] [Related]
12. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
[TBL] [Abstract][Full Text] [Related]
13. Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder.
Lundin NB; Sepe-Forrest L; Gilbert JR; Carver FW; Furey ML; Zarate CA; Nugent AC
J Affect Disord; 2021 Jan; 279():239-249. PubMed ID: 33074143
[TBL] [Abstract][Full Text] [Related]
14. Translational control by ketamine and its implications for comorbid cognitive deficits in depressive disorders.
Lewis V; Rodrigue B; Arsenault E; Zhang M; Taghavi-Abkuh FF; Silva WCC; Myers M; Matta-Camacho E; Aguilar-Valles A
J Neurochem; 2023 Jul; 166(1):10-23. PubMed ID: 35680556
[TBL] [Abstract][Full Text] [Related]
15. Guanosine as a promising target for fast-acting antidepressant responses.
Camargo A; Rodrigues ALS
Pharmacol Biochem Behav; 2022 Jul; 218():173422. PubMed ID: 35732211
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation.
Gilbert JR; Zarate CA
Pharmacol Biochem Behav; 2020 Feb; 189():172856. PubMed ID: 31958471
[TBL] [Abstract][Full Text] [Related]
17. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms.
Krystal JH; Kavalali ET; Monteggia LM
Neuropsychopharmacology; 2024 Jan; 49(1):41-50. PubMed ID: 37488280
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of ketamine's antidepressant effect: An umbrella review.
Meshkat S; Ho RC; Cao B; Teopiz KM; Rosenblat JD; Rhee TG; Di Vincenzo JD; Ceban F; Jawad MY; McIntyre RS
J Affect Disord; 2023 Feb; 323():598-606. PubMed ID: 36521662
[TBL] [Abstract][Full Text] [Related]
19. Ketamine for depression.
Jelen LA; Stone JM
Int Rev Psychiatry; 2021 May; 33(3):207-228. PubMed ID: 33569971
[TBL] [Abstract][Full Text] [Related]
20. Ketamine: Mechanisms and Relevance to Treatment of Depression.
Kim JW; Suzuki K; Kavalali ET; Monteggia LM
Annu Rev Med; 2024 Jan; 75():129-143. PubMed ID: 37729028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
